Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Another Setback : SC...

    Another Setback : SC rejects petition by Singh brothers against Daiichi's arbitration award

    Written by Ruby Khatun Khatun Published On 2018-02-16T09:50:47+05:30  |  Updated On 16 Feb 2018 9:50 AM IST
    Another Setback : SC rejects petition by Singh brothers against Daiichis arbitration award

    New Delhi: Another setback has come to Singh brothers as the Supreme Court today rejected their petition for seeking permission to appeal a High Court judgment allowing Daiichi Sankyo to recover about Rs 3,500 crores from them as part of an international arbitration award.


    With the decision of the apex court, Singh brothers have almost worn out their legal alternative in India to block the arbitration award.


    As per the Mint report, the two-judge bench consisting justice Ranjan Gogoi and justice R Banumathi said that “We are not inclined to interfere” with Delhi High Court’s judgment.


    On February 7, Singh brothers had filed a special leave petition in the Supreme Court to challenge the high court decision in favour of Daiichi Sankyo after the Delhi High Court allowed Daiichi to enforce an arbitral award of Rs 3,500 crore.


    Read also: Rs 3,500 crore jolt to Singh brothers as Delhi High Court upholds the arbitral award

    In May 2016, Daiichi had approached the high court to recover this amount as part of an international arbitration award granted against the Singh’s for allegedly hiding the information of misconduct at Ranbaxy while selling the company to them for $4.8 billion in 2008.


    Following objections to the enforcement by the Singh brothers, the Delhi High Court on January 31 ruled in favour of Daiichi.

    Singh brothers were found guilty by the HC for making false claims in a self-assessment report and of unfairly misrepresenting and concealing the genesis, nature, and severity of the US regulatory investigations of Ranbaxy when Daiichi bought in 2008.


    However, Singh brothers have also appealed the award in Singapore, where it was first granted in April 2016. The matter is expected to be argued by Harish Salve and Gopal Subramanium, counsels for the Singhs and Daiichi in the foreign court, respectively.
    Daiichi SankyoGopal SubramaniumHarish SalveHigh CourtJustice R BanumathiJustice Ranjan GogoipetitionRanbaxySCSingh brothersSupreme Court
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok